Abaco Capital (ABA LN) Business update: likely capital return to shareholders | Clinigen Group (CLIN LN) In line H1, but FX and weak CTS take the shine off H2 | Conviviality (CVR LN) Feedback post round table meeting | Devro (DVO LN) Plenty of positives in FY17 finals | Dialight (DIA LN) Looking for a better buying opportunity | dotdigital Group (DOTD LN) Progress on all fronts | Elementis (ELM LN) A year of progress and a promising outlook for FY18 | James Fisher & Sons (FSJ LN) Solid results: ....
27 Feb 2018
Morning Song
Abaco Capital (ABA:LON), 0 | Conviviality (CVR:LON), 0 | Dialight plc (DIA:LON), 257 | DotDigital Group PLC (DOTD:LON), 71.0 | Elementis plc (ELM:LON), 160 | James Fisher and Sons plc (FSJ:LON), 398 | PCI-PAL PLC (PCIP:LON), 46.0 | Realm Therapeutics (RLM:LON), 0 | Summit Therapeutics Inc (SMMT:NAS), 0
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Morning Song
Abaco Capital (ABA:LON), 0 | Conviviality (CVR:LON), 0 | Dialight plc (DIA:LON), 257 | DotDigital Group PLC (DOTD:LON), 71.0 | Elementis plc (ELM:LON), 160 | James Fisher and Sons plc (FSJ:LON), 398 | PCI-PAL PLC (PCIP:LON), 46.0 | Realm Therapeutics (RLM:LON), 0 | Summit Therapeutics Inc (SMMT:NAS), 0
- Published:
27 Feb 2018 -
Author:
Singer CM Team -
Pages:
25 -
Abaco Capital (ABA LN) Business update: likely capital return to shareholders | Clinigen Group (CLIN LN) In line H1, but FX and weak CTS take the shine off H2 | Conviviality (CVR LN) Feedback post round table meeting | Devro (DVO LN) Plenty of positives in FY17 finals | Dialight (DIA LN) Looking for a better buying opportunity | dotdigital Group (DOTD LN) Progress on all fronts | Elementis (ELM LN) A year of progress and a promising outlook for FY18 | James Fisher & Sons (FSJ LN) Solid results: ....